In vitro activity of ceftazidime-avibactam against gram-negative bacteria in patients with bacteremia and skin and soft-tissue infections in Colombia 2019-2021.

Autor: Lemos-Luengas EV; Medical Affairs Pfizer Colombia, Colombia; Foundation For Development And Support In International Health (FUDASAI), Miami, FL, USA. Electronic address: elkin799@yahoo.com., Rentería-Valoyes S; Medical Affairs Pfizer Colombia, Colombia., Muñoz DMA; Medical Affairs Pfizer Colombia, Colombia., Gonzalez CKG; Medical Affairs Pfizer Colombia, Colombia., Guerrón-Gómez G; Universidad de La Sabana, Chía Colombia., Ramos-Castaneda JA; Research Group Innovación y Cuidado, Faculty of Nursing, Universidad Antonio Nariño, Neiva, Colombia.
Jazyk: angličtina
Zdroj: Diagnostic microbiology and infectious disease [Diagn Microbiol Infect Dis] 2024 Jun; Vol. 109 (2), pp. 116235. Date of Electronic Publication: 2024 Feb 29.
DOI: 10.1016/j.diagmicrobio.2024.116235
Abstrakt: Objectives: Ceftazidime-avibactam (CAZ-AVI) is an option for infections caused by MDR gram-negative bacilli. In this study, we aimed to analyze the in vitro antimicrobial activity of CAZ-AVI and other antimicrobial agents against gram-negative bacilli that were collected in Colombia between 2019 and 2021 from patients with bacteremia and skin and soft-tissue infections (SSTIs).
Methods: A total of 600 Enterobacterales and 259 P. aeruginosa strains were analyzed. The phenotypic resistance of isolates, particularly non-susceptibility to meropenem, multidrug-resistant (MDR) isolates, and difficult-to-treat (DTR) P. aeruginosa, was evaluated according to CLSI breakpoints.
Results: Enterobacterales had the most susceptibility to CAZ-AVI (96.5 %) and tigecycline (95 %). Tigecycline and CAZ-AVI were the antimicrobial agents with the most in vitro activity against carbapenem-resistant Enterobacterales (CRE). CAZ-AVI was the antimicrobial treatment with the most activity against P. aeruginosa.
Conclusions: Tigecycline and CAZ-AVI were the antimicrobial agents with the most activity against CRE and MDR Enterobacterales. For P. aeruginosa, CAZ-AVI was the antimicrobial treatment with the most in vitro activity.
Competing Interests: Declaration of competing interest The authors declare the following financial interests/personal relationships which may be considered as potential competing interests: Elkin Lemos-Luengas, works in Medical Affairs Pfizer S.A.S Colombia Sixta Renteria, works in Medical Affairs Pfizer S.A.S Colombia Diana Marcela Almario Muñoz, works in Medical Affairs Pfizer S.A.S Colombia Cinthya Katherine Galindo Gonzalez, works in Medical Affairs Pfizer S.A.S Colombia Jorge Andres Ramos-Castaneda, has provided consulting services for Pfizer S.A.S
(Copyright © 2024 The Authors. Published by Elsevier Inc. All rights reserved.)
Databáze: MEDLINE
Externí odkaz: